Why do prices not converge? A theoretical assessment


Kanavos and Costa-Font contradict the standard arbitrage hypothesis of price competition and the race towards the bottom in the importing countries. They reject the hypothesis of price convergence among exporting and importing countries for Europe as a whole 108. Evidence from Sweden suggests that pharmaceutical companies respond to parallel traded competition by reducing their list prices, though to a level which is higher than what parallel traders are charging. Price reductions in Sweden may, therefore, have another purpose than deterring parallel trade. The reason why pharmaceutical companies reduce their list prices may, nevertheless, be parallel trade.


Marginal Cost Drug Manufacturer Destination Country Domestic Demand List Price 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 108.
    P. Kanavos, J. Cost Font (2005), Economic Policy October 2005, pp 751–798Google Scholar
  2. 109.
    Ganslandt M and Maskus K (2004): J. of Health Economics 23 (2004) 1035–1057, p. 1049 and Ganslandt M and Maskus K (2001): Working Paper No 546, 2001, IUI, StockholmCrossRefGoogle Scholar
  3. 111.
    Cambridge Pharma Consultancy (2006), Pricing and Market Access Review, p. 8Google Scholar

Copyright information

© Birkhäuser Verlag AG 2008

Personalised recommendations